Intravitreal pegaptanib for refractory macular edema secondary to retinal vein occlusion.

Objective: To assess the efficacy of intravitreal Pegaptanib sodium (Macugen(®)) injection in the management of refractory macular edema secondary to branch retinal vein occlusion.

Methods: This is a prospective, nonrandomized, interventional case series. Five eyes of five patients with macular edema refractory to either bevacizumab or triamcinolone were treated with intravitreal injection of Pegaptanib sodium.

Results: After three months follow-up, both visual acuity and macular edema, measured by optical coherence tomography and fluorescence angiography, dramatically improved.

Conclusions: Pegaptanib sodium is a safe and efficacy treatment for macular edema secondary to branch retinal vein occlusion.